
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 5.960 | 5.960 | 0.000 |
Shares | 94.040 | 94.040 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 31.077 | 28.596 |
Price to Book | 8.878 | 6.745 |
Price to Sales | 9.017 | 4.961 |
Price to Cash Flow | 24.341 | 19.249 |
Dividend Yield | 0.403 | 0.694 |
5 Years Earnings Growth | 16.281 | 13.439 |
Name | Net % | Category Average |
---|---|---|
Technology | 39.950 | 36.500 |
Financial Services | 19.630 | 11.065 |
Healthcare | 14.000 | 13.105 |
Communication Services | 9.730 | 12.440 |
Consumer Cyclical | 9.100 | 14.649 |
Industrials | 7.580 | 7.686 |
Number of long holdings: 23
Number of short holdings: 6
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
NVIDIA | US67066G1040 | 7.17 | 108.73 | -2.05% | |
Netflix | US64110L1061 | 7.09 | 1,110.38 | +0.80% | |
ASML ADR | USN070592100 | 6.81 | 672.76 | -0.67% | |
Visa A | US92826C8394 | 5.74 | 337.51 | +0.70% | |
Intuit | US4612021034 | 4.91 | 618.23 | -0.94% | |
Synopsys | US8716071076 | 4.78 | 443.97 | -0.59% | |
Airbnb | US0090661010 | 4.74 | 123.30 | +0.64% | |
S&P Global | US78409V1044 | 4.56 | 479.37 | -0.13% | |
Eli Lilly | US5324571083 | 4.44 | 877.29 | -0.82% | |
Intuitive Surgical | US46120E6023 | 4.39 | 514.01 | -0.11% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Adamant Medtech I USD | 1.41B | 3.45 | 1.70 | 9.65 | ||
Adamant Medtech B USD | 1.41B | 3.28 | 0.99 | 8.87 | ||
LU1811047247 | 218.95M | 4.69 | -10.13 | - | ||
LU1811047593 | 218.95M | 3.96 | -10.76 | - | ||
Ashburton Glbl Leaders EqI USD Acc | 172.67M | 3.00 | 5.85 | 7.43 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review